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ABSTRACT
Objective To evaluate the effectiveness of the community
based Cardiovascular Health Awareness Program (CHAP)
on morbidity from cardiovascular disease.
Design Community cluster randomised trial.
Setting 39 mid-sized communities in Ontario, Canada,
stratified by location and population size.
ParticipantsCommunitydwellingresidentsaged65years
or over, family physicians, pharmacists, volunteers,
community nurses, and local lead organisations.
Intervention Communities were randomised to receive
CHAP (n=20) or no intervention (n=19). In CHAP
communities, residents aged 65 or over were invited to
attend volunteer run cardiovascular risk assessment and
educationsessionsheldincommunitybasedpharmacies
over a 10 week period; automated blood pressure
readings and self reported risk factor data were collected
and shared with participants and their family physicians
and pharmacists.
Main outcome measure Composite of hospital
admissions for acute myocardial infarction, stroke, and
congestive heart failure among all community residents
aged 65 and over in the year before compared with the
year after implementation of CHAP.
Results All 20 intervention communities successfully
implemented CHAP. A total of 1265 three hour long
sessions were held in 129/145 (89%) pharmacies during
the 10 week programme. 15889 unique participants had
a total of 27358 cardiovascular assessments with the
assistance of 577 peer volunteers. After adjustment for
hospital admission rates in the year before the
intervention, CHAP was associated with a 9% relative
reductioninthecompositeendpoint(rateratio0.91,95%
confidence interval 0.86 to 0.97; P=0.002) or 3.02 fewer
annual hospital admissions for cardiovascular disease
per 1000 people aged 65 and over. Statistically
significant reductions favouring the intervention
communities were seen in hospital admissions for acute
myocardial infarction (rate ratio 0.87, 0.79 to 0.97;
P=0.008)andcongestiveheartfailure(0.90,0.81to0.99;
P=0.029) but not for stroke (0.99, 0.88 to 1.12; P=0.89).
Conclusions A collaborative, multi-pronged, community
based health promotion and prevention programme
targeted at older adults can reduce cardiovascular
morbidity at the population level.
Trial registration Current controlled trials
ISRCTN50550004.
INTRODUCTION
In2002theWorldHealthOrganizationidentifiedhigh
bloodpressureastheleadingriskfactorfordeath,fore-
casting an epidemic of hypertension and identifying
community programmes to prevent cardiovascular
disease as a priority.
1 Worldwide, 30% of all deaths
are due to cardiovascular disease, and more than 54%
of deaths from stroke, 47% of those from ischaemic
heart disease, and 14% of all deaths are attributable to
highbloodpressure.
23Effectivepopulationbasedstra-
tegies for health promotion and disease prevention,
bothforpeoplewithestablishedcardiovasculardisease
andforthoseatriskofdevelopingit,areseenascritical
to countering widespread and growing epidemics of
obesity, hypertension, diabetes, heart disease, and
stroke.
4-6 Both the incidence and the prevalence of
hypertension increase with age, and the lifetime resi-
dualriskofdevelopinghypertensionforamiddleaged
person with normal blood pressure is 90%.
7
A recent review of community programmes for pre-
ventionofcardiovasculardiseaseincluded36commu-
nity programmes that took place between 1970 and
2008 and concluded that although generally favour-
able changes in overall cardiovascular risk have been
shown, considerable uncertainties about their effec-
tiveness remain.
8 The review further concluded that
studies of programmes better adapted to current
circumstances need to be implemented and rigorously
evaluated before widespread implementation of
such programmes can be recommended. Specific
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grammes implemented in the past included the selec-
tion of appropriate control groups and the mode of
collection of outcome data.
As a large fraction of cardiovascular disease is attri-
butabletomodifiablefactors,findinganeffectivecom-
bination of approaches to improve awareness and
prevention of risk factors is a high priority. We postu-
lated that a locallydelivered but standardisedand cen-
trally supported programme of cardiovascular health
promotion and disease prevention targeting older
adults could lead to improved management of
cardiovascular risk factors and thus reduce morbidity
at the population level.
METHODS
Study area and population
Ontario is Canada’s most populous province, with
approximately 13 million residents. We identified all
municipalities in Ontario with a population of 10000
to 60000, according to the 2001 Canadian census
(n=41). We considered communities of this size to be
optimal trial sites in terms of both standardised imple-
mentation and evaluation. We excluded two commu-
nities where the intervention was pilot tested.
9 The
remaining 39 communities had a total population of
973246 in 2005, including 140642 people aged
65 years or over.
Study design
This study was a two arm cluster randomised con-
trolled trial. A more detailed description of the study
design,
10 development of the Cardiovascular Health
AwarenessProgram(CHAP),
91112andCHAP’simple-
mentation have been published previously.
13 In brief,
we stratified the 39 eligible communities, geographi-
cally defined according to municipal boundaries, by
populationsize(threestrata)andgeographicallocation
(four strata). An independent expert in cluster rando-
mised trials then used a random number generator to
randomly allocate communities in each stratum to
receive either CHAP (n=20) or no intervention
(n=19). In both arms, residents received the usual
health promotion and healthcare services available to
all Ontarians under its publicly financed universal
health insurance programme.
Although participants were informed that CHAP
was being evaluated, we did not publicise the fact that
evaluation was by a community randomised trial. To
understand potential co-intervention and contamina-
tion, we identified public health units and other agen-
ciesinallstudycommunitiesandcontactedtheminthe
year after the intervention to determine whether
important cardiovascular health initiatives occurred
during the study period.
CHAP intervention
The CHAP intervention was standardised and con-
sisted of 10 weeks of three hour weekday blood pres-
sure and cardiovascular risk factor assessment and
educational sessions held concurrently in all 20 inter-
vention communities during the autumn of 2006. The
box lists the essential elements of CHAP. Local agen-
ciesrecruitedandtrainedvolunteerpeerhealtheduca-
tors to help participants measure their blood pressure
by using a validated, automated instrument (BpTRU,
VSM MedTech, 2004). Blood pressure readings and
other information on cardiovascular risk factors were
recorded and, with participants’ consent, sent to their
family physician and usual pharmacist. CHAP volun-
teers supportedself management by providing partici-
pants with their risk profile, risk specific educational
materials, and information about availability of and
Essential elements of CHAP*
1. Scope of programme: community-wide orientation
 Community-wide orientation with a view to reaching all people in the community who
are part of the broad “target audience” (residents aged 65 years or over)
 Cardiovascular risk assessment sessions offered free of charge
2. “Closing the loop”: linkage to appropriate healthcare providers
 Family physicians, nurse practitioners, and pharmacists involved in referral/invitation
to the programme and receiving feedback of patients’ results
3. Accessible location/setting and enhanced continuity of care
 Regular weekly session held in community pharmacies (with appropriate healthcare
professional present)
 Continuity of care (integrated healthcare) enhanced through explicit links between
pharmacists and family physicians
4. Blood pressure measurement device and accurate measurement of blood pressure
 Use of a validated and accurate blood pressure measuring device (such as the BpTRU)
 Volunteers trained to measure blood pressure accurately
5. Referral for follow-up
 Blood pressure and chronic disease risk profile results used according to CHAP
protocol to ensure that participants in CHAP pharmacy sessions are linked to
appropriate health providers and resources
6. Global cardiovascular risk factor assessment and education
 Maintaining “global” risk factor assessment
 Aiming to increase awareness of modifiable risk factors for chronic disease, including
cardiovascular disease and stroke
 Availability of resources and linkage to other local and provincial/national sources of
information/programmes for modifiable risk factors
7. Feedback of results
 Transfer of all CHAP pharmacy sessions’ results to primary healthcare provider(s), with
participants’ consent:
 For participants at high risk with CHAP protocol
 For all participants with CHAP summarised participants’ results report form
 Comparative feedback to family physicians
8. Evaluation
 Process evaluation data collected for the purpose of ongoing evaluation and quality
improvement:
 Success of different advertising/invitation strategies
 Attendance, consent, completed assessments
 Nurse assessments, pharmacist consults, fax/call to familyphysician thesame day
 Feedback to family physicians, pharmacists, and participants
*SeeCHAP Implementation Guide (www.CHAPprogram.ca) for more information
RESEARCH
page 2 of 8 BMJ | ONLINE FIRST | bmj.comaccess to local community resources. A community
health nurse ensured immediate follow-up of partici-
pants identified as being at high risk on the basis of
theirsystolicbloodpressure,andanon-sitepharmacist
was available for drug related consultations.
We used “fax to database” technology to compile
results from all sessions and forwarded them to family
physicians at the end of the 10 week programme.
Reports rank ordered their patients by their most
recent systolic blood pressure within diagnostic/treat-
ment groups (potentially new cases of hypertension
and potentially under-treated/non-adherent patients)
and, to reflect different blood pressure targets for
patients with diabetes, self reported diabetes status.
Six months after the end of sessions, family physicians
received a copy of this report again, along with feed-
back showing the percentageof their patientswith and
without diabetes who reached systolic blood pressure
target levels compared with those of other family phy-
sicians in their own community and of family physi-
cians in all intervention communities combined.
CHAP implementation
Weinvitedorganisationswithaninterestinhealthpro-
motion and experience in working with volunteers or
volunteer run programmes, through a request for pro-
posals,to implement CHAP as the local lead organisa-
tions in each community. Thesuccessful organisations
represented a spectrum of community agencies, from
hospitalsandseniors’centrestoprimarycareandcom-
munity support organisations. Each received between
$C20000 (£13000; €15000) and $C40000 to support
implementation of CHAP.
We encouraged the local lead organisations and
their coordinators to use opinion leaders and peers to
gainthesupportandparticipationoffamilyphysicians
and pharmacies.
14 We invited all family physicians
with an office address in an intervention community
to participate.Participation involvedsending persona-
lised invitations, hand distributing referral letters, and
encouraging their patients aged 65 and older to attend
the CHAP sessions. When required, CHAP support
staff produced and mailed invitation letters on behalf
of participating physicians. We invited all community
based pharmacies located in the intervention commu-
nities to participate. Participation involved providing
space and pharmacist support during CHAP sessions
and encouraging clients to participate.
The local lead organisations used several strategies
to recruit volunteer peer health educators. These stra-
tegies included using the local lead organisation’s
existing volunteer base, advertising in the local
media, and giving presentations at local seniors’
clubs.Thevolunteersweretrainedaccordingtoastan-
dardised curriculum developed by a public health
nurse and delivered by nurses working in each inter-
vention community.
Anyonevisitingaparticipatingpharmacycouldtake
part in a CHAP session. However, people aged
65 years or over were explicitly targeted. In addition
to invitations and referrals from participating family
Control (n=19 communities)
CHAP not offered
Intervention (n=20 communities)
Communities mobilised to offer CHAP sessions 
with feedback of results to family physicians
8 Months:
Eligible Ontario communities
(population between 10 000 and 60 000; ≥5 family physicians; ≥2 pharmacies) (n=39)
Retrospective assessment of primary outcome measure event rates at community level
(1 September 2005 to 31 August 2006: “pre-intervention period”)
Community cluster randomisation stratified by size of population 65 years of age (3 strata)
and geographical location (4 strata)
Assessment of post-intervention primary
and secondary outcomes at community level 
(1 September 2007 to 31 August 2008: “post-intervention period”)
January to August 2006
Request for proposals for funding to deliver CHAP; local lead organisations chosen and local
CHAP coordinators hired
a
b
c
d
i
j
g 5 Months:
7 Months:
e f h
a
12 Months:
Mobilisation activities by local lead organisation, including documentation of local
capacities (such as stakeholders, programmes, and agencies), review and collection of
information and education resources, planning and delivery of stakeholder meetings,
identification of physician opinion leader and pharmacist champion, development of action
plan to implement CHAP
b
Implementation activities led by the local CHAP coordinator with support from local lead
organisations, including hiring community health nurse, recruiting family physicians and
pharmacies, recruiting and training volunteer peer health educators, implementing invitation
methods, and developing CHAP session schedules
September to November 2006
Participants assisted by volunteer peer health educators to complete the cardiovascular
disease and stroke risk profile
Participants assisted by volunteer peer health educators to measure their blood pressure
(BP) with BpTRU automated device and record result
e
Copy of completed risk profile given to each participant and faxed to database h
On-call nurse called to reassess participants identified as being at high risk (systolic BP 180
or diastolic BP 110 mm Hg); family physician contacted and provided with session results by
fax same day 
c
f
d
January 2007
Pharmacy session results for 10 week programme sent to participants’ family physicians in
form of reports rank ordering their patients by systolic BP (from highest to lowest) and
diagnostic/treatment status
i
May to August 2007
Aggregate level comparative feedback along with individual patient data sent to family
physicians showing BP control of patients from their practice who participated in CHAP
compared with patients of other family physicians in their own community and across all 20
intervention communities
j
Participants provided with targeted educational resources by volunteer peer health educators
on basis of risk profile responses
g
Profile of CHAP trial, including main components of intervention. CHAP=Cardiovascular Health
Awareness Program
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we advertised CHAP sessions by using flyers, posters,
andpaidandunpaidadvertisementsinthelocalmedia.
We coordinated CHAP centrally throughout the
study. This took the form of weekly teleconferences
with the central CHAP team, local coordinators,
monthly newsletters, an interactive web forum, and
site visits toassistwith promotionand implementation
ofCHAP.Othercentralisedservicesincludedprepara-
tion of community profiles from secondary data
sources, including sociodemographic characteristics,
prevalence of cardiovascular risk factors, and lists of
family physicians, pharmacies, and local cardio-
vascular disease resources; cardiovascular disease
risk assessment forms; promotional posters and press
releasetemplates;theimplementationguide(available
at www.CHAPprogram.ca) comprising week by week
guidance and materials for recruitment, training, and
retention of volunteers, strategies for recruiting family
physiciansandpharmacists,andcommunications;and
electronic data management services. Two regional
coordinators provided support to the local CHAP
coordinators and their local lead organisations.
Evaluation
Evaluation of the programme was independent of its
implementation and relied on routinely collected,
population based administrative health data housed
at the Institute for Clinical Evaluative Sciences (www.
ices.on.ca). Data sources included hospital discharge
abstracts from the Canadian Institute for Health Infor-
mation, physician service claims from the Ontario
Health Insurance Program, and prescription drug
claims from the Ontario Drug Benefit Program.
These datasets have been used extensively in health
services research, and the core data elements have
high levels of completeness and validity.
The primary outcome measure was the relative
change in the mean annual rate of hospital admissions
with a “most responsible” (primary) discharge diagno-
sis of acute myocardial infarction, congestive heart
failure, or stroke (composite end point) among com-
munity dwelling residents aged 65 years and over in
the year before compared with the year after imple-
mentation of CHAP. Because of the short follow-up
period, we elected to use a composite end point to
increase the event rates and thus the statistical power.
The study admissions were coded in the Canadian
Institute for Health Information’s discharge abstract
database with ICD-10-CA (international classification
of diseases, 10th revision, Canadian enhancement).
The diagnoses comprising the primary outcome mea-
sure were validated and have high positive predictive
value.
15-18 Because the data are population based, hos-
pital admissions could be attributed to patients’ place
of residence regardless of where they occurred.
Secondary outcome measures included mortality
duringtheabovehospitaladmissions,allcausemortal-
ity, and newly prescribed antihypertensive drug
treatment.
19
Statistical analysis
The sample size was pre-determined, as only 39 com-
munities in Ontario met our eligibility criteria. We
used rates of hospital admission for acute myocardial
infarction, congestive heart failure, and stroke in these
39 communities and the 2001 census population esti-
mates for people aged 65 years and over for power
calculations. In 2001, a total of 11486 such hospital
admissions occurred, with 148589 person years of
observations, giving an overall admission rate of 77.3
per 1000 person years. The standard deviation of the
observed admission rates was 17.9. With the assump-
tion that the mean hospital admission rate in control
communities remained constant, 19 communities per
armalloweddetectionofa 21%or greaterreductionin
the mean annual rate of hospital admission with 80%
power (using a two tailed test at the α=0.05 level of sig-
nificance).
We did the primary analysis according to intention
to treat; because treatment allocation was by cluster,
we used the cluster as the unit of analysis. Hospital
admissions of interest occurred between 1 September
2005 and 31 August 2006 (“pre-intervention period”)
and between 1 September 2007 and 31 August 2008
(“post-intervention period”). We then calculated rates
as the ratio of the cumulative number of study resi-
dents’ hospital admissions over the population size of
the community. To identify the contribution of multi-
ple admissions for individual people, we also calcu-
lated rates by using the number of unique people
admitted per period. The primary outcome at the
admission level allowed for multiple hospital admis-
sions, whereas the patient level analyses included the
first admissions only. These analyses allowed estima-
tion of the effect of CHAP on the secondary, patient
level outcomes. The population denominator was the
number of community dwelling people aged 65 years
and over who were alive and residing in each study
community on the first day of the pre-intervention
Table 1 |Baseline characteristics of CHAP trial communities (on 1 September 2006). Values
are means (SD)
Control communities
(n=19)
Intervention communities
(n=20)
Demographic characteristics
No of residents aged ≥65 years 3829.89 (2176.44) 3393.70 (1831.59)
Age (years) 74.79 (0.43) 74.82 (0.62)
Male sex (%) 42.65 (1.19) 42.92 (2.16)
Rurality index
20 28.96 (13.60) 31.63 (14.09)
Low income status (%)* 16.95 (8.55) 18.57 (11.33)
Morbidity
No of prescription drugs in previous year 7.25 (0.49) 6.98 (0.54)
No of comorbidity groups in previous 2 years
21 7.31 (0.30) 7.17 (0.50)
Charlson comorbidity index in previous 2 years
22 0.57 (0.09) 0.58 (0.11)
Diabetes (%)
23 22.16 (2.34) 21.20 (2.79)
History of congestive heart failure (%)
24 12.19 (1.91) 12.45 (2.34)
Mortality
Death rate per 100 in previous year 3.45 (0.40) 3.55 (0.57)
*Member of lowest fifth of neighbourhood income in 2006 Canadian census.
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.comandpost-interventionperiodsaccordingtotheOntario
registered persons database.
Foreachoutcome,wefittedlinearregressionmodels
by using the Poisson distribution and the log linkfunc-
tion.Thedependentvariablewasthepost-intervention
count (that is, number of hospital admissions during
the post-intervention period), and we regressed
this on the intervention indicator (1=intervention
community (n=20), 0=control community (n=19))
and the pre-intervention count. We used the log of
the post-intervention population size as an offset para-
meter. We calculated relative rates (that is, event rates
for intervention communities versus control commu-
nities)and95%confidenceintervalsbyexponentiating
the parameter estimate of the intervention indicator.
We used SAS 9.1.2 for all analyses.
RESULTS
The figure shows the trial profile. Table 1 shows key
baselinecharacteristicsforthetwostudyarms.Noneof
the differences between the intervention and control
communitiesatbaselinereachedstatisticalsignificance
at the conventional level. The mean number of resi-
dents aged 65 years and over in the 39 study commu-
nities was 3606 (SD 1992), their mean age was 74.8
(0.53) years, and 42.8% (1.74%) were male.
All 20 intervention communities successfully imple-
mented CHAP. A total of 1265 three hour long ses-
sions were held in 129/145 (89%) pharmacies during
the 10 week programme. In all, 15889 unique partici-
pants had a total of 27358 cardiovascular assessments
with the assistance of 577 peer volunteers: 84.2%
(13379) of participants were 65 years of age or over.
Overall, 214/341 (63%) family physicians sent 24196
personalisedinvitationletters,and338(99%)agreedto
receive assessment results.
Table 2 shows the rates of hospital admission for
cardiovascular disease according to trial arm and
studyphase,aswellastheratiooftheseratescalculated
asthenumberofcumulativeadmissionsofpeopleaged
65yearsorolderperperiodoverthecommunitypopu-
lation size. In the pre-intervention (baseline) period,
2243 hospital admissions for acute myocardial infarc-
tion, stroke, or congestive heart failure (our composite
primary end point) occurred among residents aged
65 years and over in control communities (mean rate
29.36 per 1000) and 2032 (30.15 per 1000) in CHAP
communities. In the post-intervention period, 2318
(30.13 per 1000) hospital admissions occurred in con-
trol communities and 1915 (27.90 per 1000) in the
intervention communities. After adjustment for hospi-
tal admission rates in the year before the intervention,
exposure to CHAP was associated with a 9% relative
reduction in our composite primary end point (rate
ratio 0.91, 95% confidence interval 0.86 to 0.97;
P=0.002) or 3.02 fewer annual hospital admissions for
cardiovascular disease per 1000 people aged 65 years
and over. We found statistically significant reductions
favouring the intervention communities in hospital
admissions for acute myocardial infarction (rate ratio
0.87, 0.79 to 0.97; P=0.008) and congestive heart fail-
ure (0.90, 0.81 to 0.99; P=0.029) but not for stroke
(0.99, 0.88 to 1.12; P=0.89) (table 2). The patterns
were similar when results were expressed in terms of
numberofuniquepeopleadmittedtohospital(table 3),
although fewer outcomes reached statistical signifi-
cance at conventional levels.
Table 3 shows the rates of hospital admission for
cardiovascular disease, as well as the secondary out-
comes rates, according to trial arm and study phase
and the ratio of these rates calculated as the number
of unique people aged 65 years and older per period
over the community population size. Analysis of sec-
ondary outcomes showed a statistically significant dif-
ference favouring the CHAP intervention in newly
prescribed antihypertensive drug treatment (rate ratio
1.10, 1.02 to 1.20; P=0.020), a trend towards lower in-
hospital cardiovascular mortality (0.86, 0.73 to 1.01;
P=0.06),andnodifferenceintermsofallcausemortal-
ity (0.98, 0.92 to 1.03; P=0.38) (table 3).
Apart from CHAP, no important cardiovascular
health promotion initiatives occurred during the
study period that could account for our findings.
DISCUSSION
Thisstudyisanimportantstepforwardforcommunity
based cardiovascular health promotion programmes,
showing reductions in rates of hospital admission for
cardiovasculardiseasethatweresignificantbothstatis-
tically and from a population health perspective. The
findings are encouraging given the short duration of
boththeCHAPinterventionandthefollow-upperiod.
Furthermore, CHAP was successfully implemented in
all 20 randomly selected communities, suggesting that
the programme’s components, tools, and processes
were feasible and acceptable to diverse organisations,
healthcareproviders,andolderadultsacrossarangeof
medium sized communities.
AttherootofthesuccessofCHAPwascollaboration
with local stakeholders, including organisations
Table 2 |Comparison of mean hospital admission rates per 1000 by study arm
Hospital admissions
Pre-intervention rate (1 September
2005 to 31 August 2006)
Post-intervention rate(1September
2007 to 31 August 2008)
Rate ratio
(95% CI); P value
CHAP
(n=67 874)
Control
(n=72 768)
CHAP
(n=69 942)
Control
(n=75 499)
Composite 30.15 29.36 27.90 30.13 0.91 (0.86 to 0.97); <0.01
Acutemyocardialinfarction 10.24 10.26 9.54 10.81 0.87 (0.79 to 0.97); <0.01
Congestive heart failure 11.19 11.11 10.51 12.22 0.90 (0.81 to 0.99); 0.03
Stroke 8.71 7.99 7.86 7.10 0.99 (0.88 to 1.12); 0.89
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cians, pharmacists, community nurses, volunteers,
and local policymakers. The support of CHAP ses-
sions by family physicians helped to promote partici-
pation in the programme and timely follow-up of
participants. Perhaps the greatest source of the pro-
gramme’ssuccesswascapitalisingonandcoordinating
the institutional and human assets of each community.
These assets ranged from in-kind contributions by the
local lead organisations of facilities and materials to
politicalinfluenceandlocalconnectionstoensuresuc-
cessful implementation of CHAP. On the human
assets side, the programme relied heavily on a large
group of locally recruited, trained, and age matched
peer volunteers and the community based organisa-
tions, pharmacists, and family physicians who
embracedandsupportedtheprogrammeanditsgoals.
Strengths and limitations of study
This study successfully incorporated a randomised
clusterdesign,usedpeervolunteerstodelivertheinter-
vention,hadahighrateofparticipation,mobilisedand
coordinated prevention activities for cardiovascular
disease of both health professionals and community
organisations, and relied on population based admin-
istrative data to evaluate the intervention.
Despite its many strengths, our study has several
important limitations. Firstly, given the outcome mea-
suresandapproachtoanalysis,wecannotknowwhich
specificcomponentsofCHAPwereresponsibleforthe
observed reductions in hospital admissions for cardio-
vascular disease. We hypothesisethat several different
health provider or patient mitigated mechanisms
might have been at work. For example, CHAP com-
munities saw an increase in the rate of newly pre-
scribed antihypertensive treatment. Detection and
treatmentofpreviouslyundiagnosed,severehyperten-
sioncouldpreventhospitaladmissionsassociatedwith
acute myocardial infarction. Other postulated
mechanisms include improved adherence to guide-
lines for detectionand treatmentof cardiovascular dis-
ease by healthcare providers, improved adherence to
or starting of drug treatment or lifestyle changes by
older adults in the CHAP communities, or greater
coordination of cardiovascular disease prevention
and health promotion efforts within communities.
The reduction in admission rates for acute myocardial
infarction and congestive heart failure but not for
stroke is somewhat puzzling but may be due to the
lower incidence of stroke and the fact that these rates
declinedinbothCHAPandinterventioncommunities
during the follow-up period. The lower statistical
power associated with the lower incidence of stroke
requiringhospitaladmissionaswellasinabilitytocap-
ture the incidence of silent strokes or strokes and tran-
sient ischaemic attacks that did not necessitate
admission are additional explanations for the stroke
findings.
Secondly, we showed that CHAP was feasible and
effective in what we considered to be a manageable
number of mid-sized Ontario communities. Our find-
ingsmaynotholdforlargerurbancentresorcountries
where healthcare delivery is organised differently.
Although volunteerism is a major social phenomenon
inNorthAmerica,recruitment,training,andretention
of qualified and committed volunteers can be challen-
ging, and the use of volunteers to deliver the pro-
gramme is less feasible in countries where a tradition
of volunteerism is not well established. CHAP was
explicitly designed to target older adults, and our
approach and findings are probably not generalisable
to younger people.
Thirdly, we used standard, municipal boundaries to
define our study population. This may have led us to
underestimate the effect of the intervention if the peo-
ple who participated in CHAP resided elsewhere.
Finally, our original power calculations were based
on considerably higher hospital admission rates for
cardiovascular disease than actually occurred during
the study period. This is because in addition to a secu-
lar decline in hospital admissions for cardiovascular
disease, the rates used for the original power calcula-
tions were based on a more inclusive list of diagnosis
codesandlessrefinedpopulationestimatesusing2001
data.
Implications of findings
The modest success of previous community-wide
cardiovascular prevention initiatives has been attribu-
ted to many factors, including the potency, duration,
Table 3 |Comparison of mean number of residents admitted to hospital per 1000 by study arm
Residents admitted
Pre-intervention rate (1 September
2005 to 31 August 2006)
Post-intervention rate
(1September2007to31August2008)
Rate ratio (95% CI);
P value
CHAP
(n=67 874)
Control
(n=72 768)
CHAP
(n=69 942)
Control
(n=75 499)
Composite 24.79 24.64 23.43 24.22 0.95 (0.89 to 1.02); 0.13
Acute myocardial infarction 8.89 8.97 8.17 9.34 0.89 (0.79 to 0.99); 0.03
Congestive heart failure 9.27 9.24 8.85 9.31 0.97 (0.87 to 1.08); 0.59
Stroke 7.81 7.46 7.23 6.56 1.01 (0.89 to 1.15); 0.87
In-hospital death from
cardiovascular disease
4.35 4.46 3.88 4.66 0.86 (0.73 to 1.01); 0.06
All cause mortality 35.45 33.13 33.98 34.55 0.98 (0.92 to 1.03); 0.38
Antihypertensive treatment started 14.66 14.16 16.35* 15.31* 1.10 (1.02 to 1.20); 0.02
*1 September 2006 to 31 August 2007.
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morbidity and mortality from cardiovascular disease,
andmethodologicalweaknesses.
825Mosthavefailedto
detectchangesincardiovascularriskfactorsormortal-
ity that could unequivocally be attributed to the inter-
ventions.Althoughtheimportanceofsmallshiftsinthe
distribution of risk factors on the overall cardio-
vascular health of the population has been under-
scored repeatedly in the literature,
2627 robust
evidence supporting community-wide interventions
to precipitate such shifts remains sparse.
8
CHAP’seffectsizewasmodest,andtheoverallmor-
tality was not reduced, but this is not surprising given
the nature ofthe intervention, the oneyear durationof
the follow-up, and how we measured the effect of the
intervention. Extrapolating our results to the popula-
tion aged 65 years and above in Ontario, the United
Kingdom, and the United States would result in
approximately5000,30000,and120000fewerannual
hospital admissions for cardiovascular disease. These
estimates are on a par with the benefits of population-
wide reductions in dietary salt (2 g/day reduction),
tobacco use (elimination of 40% of use of or exposure
to tobacco), or obesity (5% reduction in body mass
indexinobesepeople)ontheannualnumberofcardio-
vascular events.
28 The reported reduction in hospital
admissions is comparable to the effect of comprehen-
sive smoke-free legislation on the incidence of acute
coronary events reported in a recent meta-analysis
(0.90, 95% confidence interval 0.86 to 0.94).
29
The projected increase in the prevalence and inci-
dence of cardiovascular disease and its consequences
isaworldwidephenomenon.Atthesametime,cardio-
vasculardiseaseishighlypreventableandmanageable
through lifestyle interventions and drug treatments.
CHAP-like, population based interventions offer an
avenue for further investigation of how the projected
effectofcardiovascularmorbiditycanbereduced.Our
currentworkfocusesonhowCHAPcanbeimplemen-
ted and sustainedlocally in a scaled down version,as a
year round programme available to every member of
the community. In addition, a comprehensive cost
effectiveness analysis is under way. Further research
at the individual level and using a broader range of
process and outcome measures is needed to help to
elucidatehowandinwhomCHAPwasmosteffective.
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